RxDoctor Payments Data

Bao Tran, MD

Interventional Cardiology · San Francisco, CANPI 1104065440

Payments from drug & device makers

$129,924in general payments, 2019–2025

Across 1,539 payments — averaging $84.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$25K
  • Medtronic$22K
  • Lexicon Pharmaceuticals, Inc.$21K
  • Abbott$9K
  • Johnson & Johnson$7K
  • Boston Scientific$7K
  • plus $38K from 54 others

What the payments were for

  • Consulting fees$15,22812%
  • Speaking & faculty fees$36,77528%
  • Travel & lodging$31,83124%
  • Food & beverage$46,01035%
  • Education$800%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer68$25,180
Medtronic(2 entities)70$21,848
Lexicon Pharmaceuticals, Inc.34$21,022
Abbott81$9,426
Johnson & Johnson83$7,310
Boston Scientific146$6,651
Cathworks, Inc.13$5,015
AstraZeneca91$2,621
Amgen97$2,313
Boehringer Ingelheim85$2,294
Novartis89$2,066
Penumbra, Inc.9$1,964
Recor Medical Inc3$1,683
Cardiovascular Systems Inc.21$1,488
E.r. Squibb & Sons, L.L.C.70$1,384
Novo Nordisk61$1,254
Sanofi-aventis U.S. LLC40$1,231
Esperion Therapeutics, Inc.48$1,200
Merck40$1,123
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)41$1,040
Pfizer56$973
Actelion Pharmaceuticals US, Inc.26$901
BD2$888
Inari Medical, Inc.13$860
Shockwave Medical, Inc10$797
Impulse Dynamics (USA) Inc.7$692
Amarin Pharma, Inc.46$641
Chiesi USA, Inc.37$591
Edwards Lifesciences12$525
Bardy Diagnostics, Inc.19$460
Abiomed5$429
Vertex1$413
Biotronik Inc.6$362
Irhythm Technologies, Inc.17$334
Alnylam Pharmaceuticals Inc.9$314
Scpharmaceuticals Inc.10$259
Kiniksa Pharmaceuticals, Ltd.8$216
Baxter Healthcare11$214
Cvrx, Inc.1$177
Kestra Medical Technology Services, Inc.2$158
Vifor Pharma, Inc.1$119
United Therapeutics Corporation1$112
Heartflow, Inc.5$109
Janssen Scientific Affairs, LLC1$100
Philips North America LLC3$98
Kiniksa Pharmaceuticals International, PLC4$94
Kowa Pharmaceuticals America, Inc.3$93
Seigla Medical, Inc.1$86
Lilly USA, LLC3$74
Astellas Pharma US Inc3$73
Lundbeck LLC3$64
Arbor Pharmaceuticals, Inc.3$63
Itamar Medical Inc1$56
Agepha Pharma FZ LLC2$39
Angiodynamics, Inc.1$38
Endotronix, Inc.1$38
Atricure, Inc.1$37
Stryker1$31
Cleerly, Inc.1$28
Elutia, Inc.1$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$129,924 in reported general payments places this provider in the 80th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$460,558
Medicare patients
702
Services billed
3,423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban399$550,025
XareltoRivaroxaban377$479,233
JardianceEmpagliflozin286$410,077
EntrestoSacubitril/Valsartan271$355,440
FarxigaDapagliflozin Propanediol207$236,034
OzempicSemaglutide99$106,143
MultaqDronedarone Hcl54$103,284
CamzyosMavacamten12$87,671
VerquvoVericiguat47$82,310
Repatha SureclickEvolocumab82$63,162
RybelsusSemaglutide22$45,242
BrilintaTicagrelor33$41,638
VeltassaPatiromer Calcium Sorbitex13$14,234
InpefaSotagliflozin17$13,236
NexletolBempedoic Acid11$11,886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$973$550,025399 claims
Johnson & JohnsonXarelto$7,310$479,233377 claims
Boehringer IngelheimJardiance$2,294$410,077286 claims
NovartisEntresto$2,066$355,440271 claims
AstraZenecaFarxiga, Brilinta$2,621$277,673240 claims
Novo NordiskOzempic, Rybelsus$1,254$151,385121 claims
Sanofi-aventis U.S. LLCMultaq$1,231$103,28454 claims
E.r. Squibb & Sons, L.L.C.Camzyos$1,384$87,67112 claims
MerckVerquvo$1,123$82,31047 claims
Lexicon Pharmaceuticals, Inc.Inpefa$21,022$13,23617 claims
Esperion Therapeutics, Inc.Nexletol$1,200$11,88611 claims
Arbor Pharmaceuticals, Inc.Edarbi$63$3,19011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →